Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 8, 2013, Pages 1457-1463

  Pond, Gregory R ^a   Armstrong, Andrew J ^b   Galsky, Matthew D ^c   Wood, Brian A ^d   Leopold, Lance ^d   Sonpavde, Guru ^e,f  

^a MCMASTER UNIVERSITY   (Canada)

^b DUKE CANCER INSTITUTE   (United States)

^c Mt Sinai Tisch Cancer Institute   (United States)

^d Ascenta Therapeutics   (United States)

^e MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

Castration resistant prostate cancer; Docetaxel; Ketoconazole; Metastatic

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; DOCETAXEL; HEMOGLOBIN; ISOSORBIDE; KETOCONAZOLE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

AGED; ANDROGEN SYNTHESIS; ARTICLE; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

CASTRATION RESISTANT PROSTATE CANCER; DOCETAXEL; KETOCONAZOLE; METASTATIC;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; GOSSYPOL; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OUTCOME ASSESSMENT (HEALTH CARE); PREDNISONE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 84886262402     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.02.008     Document Type: Article

References (31)

1. de Bono J.S., Logothetis C.J., Molina A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
2. de Bono J.S., Oudard S., Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized open-label trial. Lancet 2010, 376:1147-1154.
3. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
4. Fizazi K., Carducci M., Smith M., et al. Denosumab vs. zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomized, double-blind study. Lancet 2011, 377:813-822.
5. Parker C., Heinrich D., O'Sullivan J., et al. Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA) [abstract 1LBA]. Eur J Cancer 2011, 47(Suppl 2):3.
6. Press release Medivation and Astellas; 3 November 2011.
7. Danila D.C., Morris M.J., de Bono J.S., et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010, 28:1496-1501.
8. Attard G., Reid A.H., A'Hern R., et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009, 27:3742-3748.
9. Zhu M.L., Horbinski C.M., Garzotto M., et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 2010, 70:7992-8002.
10. Gan L., Chen S., Wang Y., et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 2009, 69:8386-8394.
11. Mostaghel E.A., Marck B.T., Plymate S.R., et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011, 17:5913-5925.
12. Cai C., Chen S., Ng P., et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is up-regulated by treatment with CYP17A1 inhibitors. Cancer Res 2011, 71:6503-6513.
13. Murillo H., Huang H., Schmidt L.J., et al. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001, 142:4795-4805.
14. Small E.J., Halabi S., Dawson N.A., et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). J Clin Oncol 2004, 22:1025-1033.
15. Sonpavde G., Matveev V., Burke J.M., et al. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol 2011 Nov 29, [Epub ahead of print].
16. Armstrong A.J., Garrett-Mayer E.S., Yang Y.C., et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis. Clin Cancer Res 2007, 13:6396-6403.
17. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials Working Group. J Clin Oncol 2008, 26:1148-1159.
18. Ryan C.J., Smith M.R., Fong L., et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010, 28:1481-1488.
19. de Bono J.S., Oudard S., Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized open-label trial. Lancet 2010, 376:1147-1154.
20. Drake C.G., Doody A.D., Mihalyo M.A., et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005, 7:239-249.
21. Mercader M., Bodner B.K., Moser M.T., et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 2001, 98:14565-14570.
22. Motzer R.J., Escudier B., Oudard S., et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 2010, 116:4256-4265.
23. Rini Bi E.B., Tomczak P., Kaprin A., et al. Axitinib vs. sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial. J Clin Oncol 2011, 29(Suppl). Abstract 4503.
24. Keunen O., Johansson M., Oudin A., et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 2011, 108:3749-3754.
25. Mancuso M.R., Davis R., Norberg S.M., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006, 116:2610-2621.
26. Ebos J.M., Lee C.R., Cruz-Munoz W., et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
27. Pàez-Ribes M., Allen E., Hudock J., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
28. Raffo A.J., Perlman H., Chen M.W., et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995, 55:4438-4445.
29. Kelly W.K., Halabi S., Carducci M.A., et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. J Clin Oncol 2010, 28(Suppl):18s. Abstr LBA4511.
30. Scher H.I., Jia X., Chi K., et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol vs. docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 2011, 29:2191-2198.
31. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.